Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc. Common Stock (ACRV) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ACRV · as of Jun 9, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Acrivon Therapeutics, Inc. Common Stock insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ACRV insider buying and selling by quarter
ACRV insider selling · ACRV insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · ACRV ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ACRV executive sell shares · ACRV board member insider trading · ACRV insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 13,729 | $25K | Form 4 |
| May 18, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | TOMSICEK MICHAEL JOHN Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Shacham Sharon Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Palani Santhosh Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Magovcevic-Liebisch Ivana Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | DiRocco Derek Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | BAUM CHARLES M Director | Award | 9,366 | — | Form 4 |
| May 18, 2026 | Peterson Katharine CAO | Award | 14,227 | — | Form 4 |
| May 18, 2026 | Mirza Mansoor Raza Chief Medical Officer | Award | 38,817 | — | Form 4 |
| May 18, 2026 | Miller Mary Chief Legal Officer | Award | 49,830 | — | Form 4 |
| May 18, 2026 | Levy Adam D. CFO | Award | 46,167 | — | Form 4 |
| May 18, 2026 | Gamelin Erick Chief Development Officer | Award | 38,584 | — | Form 4 |
| May 18, 2026 | Devroe Eric COO | Award | 72,981 | — | Form 4 |
| May 18, 2026 | Blume-Jensen Peter President and CEO · Director | Award | 180,095 | — | Form 4 |
| May 18, 2026 | Blume-Jensen Peter President and CEO · Director | Award | 72,706 | — | Form 4 |
| May 14, 2026 | Peterson Katharine CAO | Other | 99 | $190 | Form 4 |
| May 14, 2026 | Miller Mary Chief Legal Officer | Other | 184 | $353 | Form 4 |
| May 14, 2026 | Gamelin Erick Chief Development Officer | Other | 404 | $776 | Form 4 |
| May 14, 2026 | Devroe Eric COO | Other | 613 | $1K | Form 4 |
| May 14, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 1,253 | $2K | Form 4 |
| May 14, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 490 | $941 | Form 4 |
| Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Award | 3,888,888 | $7.00M⚡ | Form 4 |
| Apr 17, 2026 | Miller Mary Chief Legal Officer | Other | 558 | $993 | Form 4 |
| Feb 21, 2026 | Blume-Jensen Peter President and CEO · Director | Other | 14,265 | $22K | Form 4 |
Blume-Jensen Peter
President and CEO · Director
Date
May 21
Shares
13,729
Price
$1.79
Value
$25K
Mirza Mansoor Raza
Chief Medical Officer
Date
May 18
Shares
38,817
Price
—
Value
—
Blume-Jensen Peter
President and CEO · Director
Date
May 18
Shares
180,095
Price
—
Value
—
Blume-Jensen Peter
President and CEO · Director
Date
May 18
Shares
72,706
Price
—
Value
—
Gamelin Erick
Chief Development Officer
Date
May 14
Shares
404
Price
$1.92
Value
$776
Blume-Jensen Peter
President and CEO · Director
Date
May 14
Shares
1,253
Price
$1.92
Value
$2K
Blume-Jensen Peter
President and CEO · Director
Date
May 14
Shares
490
Price
$1.92
Value
$941
RA CAPITAL MANAGEMENT, L.P.
Director
Date
Apr 22
Shares
3,888,888
Price
$1.80
Value
$7.00M ⚡
Blume-Jensen Peter
President and CEO · Director
Date
Feb 21
Shares
14,265
Price
$1.53
Value
$22K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ACRV insider trading
ACRV insider trades
Acrivon Therapeutics, Inc. Common Stock (ACRV) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Blume-Jensen Peter (President and CEO · Director), Miller Mary (Chief Legal Officer), Devroe Eric (COO). Over the past 12 months, 5 insiders have filed transactions with the SEC. ACRV insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Acrivon Therapeutics, Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ACRV insider trading · 5 questionsThe insiders of Acrivon Therapeutics, Inc. Common Stock (ACRV) include executives and directors such as Blume-Jensen Peter (President and CEO · Director), Miller Mary (Chief Legal Officer), Devroe Eric (COO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026